Novavax Announces Positive Top-Line Data from Phase 2 RSV F-Protein Vaccine Clinical Trial in Older Adults
Go back to Novavax Announces Positive Top-Line Data from Phase 2 RSV F-Protein Vaccine Clinical Trial in Older Adults| Novavax, Inc. (NASDAQ: NVAX) | Delayed: 10.12 -0.1 (0.98%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $10.22 | 52 Week High | $9.23 | |||
| Open | $10.10 | 52 Week Low | $1.16 | |||
| Day High | $10.20 | P/E | N/A | |||
| Day Low | $9.75 | EPS | $-0.30 | |||
| Volume | 1,299,631 | |||||
